Sandra Silberman

Company: CNS Pharmaceuticals

Job title: Chief Medical Officer

Seminars:

Berubicin, An Anthracycline Analogue That Crosses the BBB, For The Treatment of GBM 10:15 am

Overview of the preclinical and Phase 1 clinical results of Berubicin in the treatment of GBM Synopsis and preliminary results of an ongoing clinical trial comparing Berubicin to Lomustine therapy for GBM after failure of first line treatment Review of safety and activity in this trial of Berubicin with the potential to establish a novel…Read more

day: Conference Day One